LOS ANGELES–(BUSINESS WIRE)–Forcyte Biotechnologies, a tech-enabled drug discovery company targeting diseases of mechanobiology, has secured new funding from Milestone View, Pioneer Fund, Acequia Capital, Y Combinator, Jude Gomila (CEO, Golden), and others. Including public support, this funding brings Forcyte’s total raised to $5.7M for their internal “mechano-therapeutic” pipeline, focusing first on fibrosis. “Contractile cell function […]

Forcyte has been awarded a $1.5M phase 2 SBIR to continue developing functional assays for cellular contractility to support programs in respiratory, hypertension, and many other indications where cellular force plays a big role. These tools will enable researchers to get to functional endpoints faster, using human cells, but without using humans. 384-wellplate products will

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on uterine contractility that will enable deeper functional studies on reproductive disorders.

Forcyte Biotechnologies has received a Phase I Small Business Innovative Research (SBIR) Grant from the National Center for Complementary and Integrative Health (NCCIH), part of the National Institutes of Health (NIH), to develop a FLECS-based assay focusing on vasodilation triggers of migraine pain that will enable rapid phenotypic screening for cranial vasoprotectors.